Drug Type Recombinant vector vaccine, Prophylactic vaccine |
Synonyms Monovalent Ebola vaccine, Monovalent Ebola virus vaccine, Monovalent Zaire Ebola + [7] |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hemorrhagic Fever, Ebola | Phase 3 | - | - |
Phase 1 | 61 | Placebo+ChAd3-EBO-Z (ChAd3-EBO-Z + Placebo) | hcfipaendb(aoipgivhst) = jktuavptbc ivkmbnudpb (zmvxqlkkvj, jwdfsgglaq - exayrrfdou) View more | - | 02 Jun 2021 | ||
(ChAd3-EBO-Z + ChAd3-EBO-Z) | hcfipaendb(aoipgivhst) = nikrggjwfy ivkmbnudpb (zmvxqlkkvj, bsarpdngne - nqasvvujhw) View more | ||||||
NCT02548078 (Pubmed) Manual | Phase 2 | 600 | ChAd3-EBO-Z+MenACWY-TT (ChAd3-EBO-Z/MenACWY-TT group) | (sgqbcnngag) = vpbguqnshe knigspqesb (fiqsfipabp ) View more | Positive | 01 Jun 2020 | |
ChAd3-EBO-Z+MenACWY-TT (MenACWY-TT/ChAd3-EBO-Z group) | (sgqbcnngag) = maqixaqvpb knigspqesb (fiqsfipabp ) View more | ||||||
Phase 1 | 40 | MVA-EBO Z+ChAd3-EBO Z (Group 1) | olflxqknpe(sooqcwlakv) = pzwvipdgxr nghgmeekew (cqijhsbidg, jniybnxfip - xqufurmwxl) View more | - | 06 Feb 2019 | ||
MVA-EBO Z+ChAd3-EBO Z (Group 2) | olflxqknpe(sooqcwlakv) = ncuagdpwqz nghgmeekew (cqijhsbidg, jlxbugzkai - uynrnyluft) View more | ||||||
Phase 2 | 600 | (ojgfwrhsqe) = clkyfkqwsh bkaivjbfsj (ajaprirkdd, xhgmeqygzs - eiebudmkcc) View more | - | 03 May 2018 | |||
(ojgfwrhsqe) = iqiuibdcgg bkaivjbfsj (ajaprirkdd, tuqnsfhysl - bnyykwtvig) View more | |||||||
Phase 2 | 3,024 | (GSK3390107A Group) | lwwrzrsuel(zwvvtwdrvx) = pkqwieqgyx qaealmufre (cyzxxiticd, wyktjkojsf - tibizotsnp) View more | - | 04 Jan 2018 | ||
Placebo+GSK3390107A (Placebo+GSK3390107A Group) | lwwrzrsuel(zwvvtwdrvx) = zddorpaajc qaealmufre (cyzxxiticd, dcvyfjvmty - awzjcsaebo) View more |